vs
Side-by-side financial comparison of Blue Foundry Bancorp (BLFY) and FENNEC PHARMACEUTICALS INC. (FENC). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $13.3M, roughly 1.0× Blue Foundry Bancorp). Blue Foundry Bancorp runs the higher net margin — -27.4% vs -34.7%, a 7.4% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 34.2%). Over the past eight quarters, Blue Foundry Bancorp's revenue compounded faster (16.0% CAGR vs -26.3%).
Blue Foundry Bancorp is a regional bank holding company based in New Jersey, United States. It offers a comprehensive range of personal and commercial banking products, including deposit accounts, consumer loans, mortgage services, and business financing solutions, serving local individual consumers and small to medium-sized enterprises.
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
BLFY vs FENC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $13.8M |
| Net Profit | $-3.5M | $-4.8M |
| Gross Margin | — | — |
| Operating Margin | — | -18.5% |
| Net Margin | -27.4% | -34.7% |
| Revenue YoY | 34.2% | 73.8% |
| Net Profit YoY | -30.6% | -141.1% |
| EPS (diluted) | $-0.18 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | $13.8M | ||
| Q3 25 | $12.6M | $12.5M | ||
| Q2 25 | $12.0M | $9.7M | ||
| Q1 25 | $11.1M | $8.8M | ||
| Q4 24 | $9.9M | $7.9M | ||
| Q3 24 | $9.5M | $7.0M | ||
| Q2 24 | $10.1M | $7.3M | ||
| Q1 24 | $9.9M | $25.4M |
| Q4 25 | $-3.5M | $-4.8M | ||
| Q3 25 | $-1.9M | $-638.0K | ||
| Q2 25 | $-2.0M | $-3.2M | ||
| Q1 25 | $-2.7M | $-1.2M | ||
| Q4 24 | $-2.7M | $-2.0M | ||
| Q3 24 | $-4.0M | $-5.7M | ||
| Q2 24 | $-2.3M | $-5.6M | ||
| Q1 24 | $-2.8M | $12.8M |
| Q4 25 | — | -18.5% | ||
| Q3 25 | — | -1.5% | ||
| Q2 25 | — | -28.3% | ||
| Q1 25 | — | -9.2% | ||
| Q4 24 | — | -11.8% | ||
| Q3 24 | — | -74.6% | ||
| Q2 24 | — | -69.4% | ||
| Q1 24 | — | 54.2% |
| Q4 25 | -27.4% | -34.7% | ||
| Q3 25 | -14.8% | -5.1% | ||
| Q2 25 | -16.2% | -32.7% | ||
| Q1 25 | -24.2% | -13.3% | ||
| Q4 24 | -28.4% | -25.0% | ||
| Q3 24 | -42.7% | -82.2% | ||
| Q2 24 | -23.2% | -76.5% | ||
| Q1 24 | -28.8% | 50.6% |
| Q4 25 | $-0.18 | $-0.17 | ||
| Q3 25 | $-0.10 | $-0.02 | ||
| Q2 25 | $-0.10 | $-0.11 | ||
| Q1 25 | $-0.13 | $-0.04 | ||
| Q4 24 | $-0.12 | $-0.02 | ||
| Q3 24 | $-0.19 | $-0.21 | ||
| Q2 24 | $-0.11 | $-0.20 | ||
| Q1 24 | $-0.13 | $0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.1M | $36.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $312.7M | $35.5M |
| Total Assets | $2.2B | $70.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.1M | $36.8M | ||
| Q3 25 | $44.1M | $21.9M | ||
| Q2 25 | $41.9M | $18.7M | ||
| Q1 25 | $46.2M | $22.7M | ||
| Q4 24 | $42.5M | $26.6M | ||
| Q3 24 | $76.1M | $40.3M | ||
| Q2 24 | $60.3M | $43.1M | ||
| Q1 24 | $53.8M | $51.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | $19.4M | ||
| Q2 25 | — | $19.4M | ||
| Q1 25 | — | $19.4M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | — | $32.1M | ||
| Q2 24 | — | $31.8M | ||
| Q1 24 | — | $31.3M |
| Q4 25 | $312.7M | $35.5M | ||
| Q3 25 | $314.4M | $-4.5M | ||
| Q2 25 | $321.3M | $-7.5M | ||
| Q1 25 | $326.7M | $-5.9M | ||
| Q4 24 | $332.2M | $-5.9M | ||
| Q3 24 | $339.3M | $-5.2M | ||
| Q2 24 | $345.6M | $-1.4M | ||
| Q1 24 | $350.2M | $3.0M |
| Q4 25 | $2.2B | $70.6M | ||
| Q3 25 | $2.2B | $49.3M | ||
| Q2 25 | $2.1B | $44.9M | ||
| Q1 25 | $2.1B | $46.4M | ||
| Q4 24 | $2.1B | $44.9M | ||
| Q3 24 | $2.1B | $58.9M | ||
| Q2 24 | $2.0B | $63.2M | ||
| Q1 24 | $2.0B | $69.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 10.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.0M | $-6.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.0M | $-6.0M | ||
| Q3 25 | $-255.0K | $1.5M | ||
| Q2 25 | $2.0M | $-3.7M | ||
| Q1 25 | $-3.8M | $-4.3M | ||
| Q4 24 | $5.1M | $-1.5M | ||
| Q3 24 | $-3.7M | $-2.2M | ||
| Q2 24 | $14.1M | $-8.4M | ||
| Q1 24 | $-4.9M | $39.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $4.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-4.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 49.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -49.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 3.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
